Acne Phase 2 - Probability of Success and Likely Market Response, page-87

I am not an expert on phase trials but the following excerpt from the link below, provides enough for me to be content with notification of interim results from the company on the psorisasis phase 1b study.



excerpt

The study involved 15 psoriasis patients who received treatment over a 19-day period either with BTX 1308, an active comparable product or a placebo. Biopsies were then taken from the treated area, as well as the untreated psoriasis and normal skin from the same patient to serve as controls.

According to Professor Krueger, the results showed the effective delivery of CBD to skin layers involved in the pathogenesis of skin disease with the drug triggering “significant alterations in inflammatory and immune response pathways”.

Of particular interest was “BTX 1308’s ability to down-regulate the p38 MAP Kinase pathway”, a key inflammatory disease pathway known to be involved in psoriasis, which Professor Krueger said was something pharmaceutical companies have tried unsuccessfully to target for many years.

Link
https://*********.com.au/botanix-study-cbd-anti-inflammatory-immune-modulating-effects-skin-disease/